Research ExplorerPublications[Prostate-specific antigen for treatment monitoring].

[Prostate-specific antigen for treatment monitoring].

Standard

[Prostate-specific antigen for treatment monitoring]. / Graefen, Markus; Fröhner, M; Wirth, M.

In: UROLOGE, Vol. 50, No. 3, 3, 2011, p. 309-312.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Graefen, M, Fröhner, M & Wirth, M 2011, '[Prostate-specific antigen for treatment monitoring].', UROLOGE, vol. 50, no. 3, 3, pp. 309-312. <http://www.ncbi.nlm.nih.gov/pubmed/21365346?dopt=Citation>

APA

Graefen, M., Fröhner, M., & Wirth, M. (2011). [Prostate-specific antigen for treatment monitoring]. UROLOGE, 50(3), 309-312. [3]. http://www.ncbi.nlm.nih.gov/pubmed/21365346?dopt=Citation

Vancouver

Graefen M, Fröhner M, Wirth M. [Prostate-specific antigen for treatment monitoring]. UROLOGE. 2011;50(3):309-312. 3.

Bibtex

@article{863d696bacfe4e628c2051b873e9181b,
title = "[Prostate-specific antigen for treatment monitoring].",
abstract = "Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.",
keywords = "Humans, Male, Prognosis, Tumor Markers, Biological/*blood, Prostate-Specific Antigen/*blood, Neoplasm Proteins/*blood, Prostatic Neoplasms/*blood/diagnosis/*therapy, Humans, Male, Prognosis, Tumor Markers, Biological/*blood, Prostate-Specific Antigen/*blood, Neoplasm Proteins/*blood, Prostatic Neoplasms/*blood/diagnosis/*therapy",
author = "Markus Graefen and M Fr{\"o}hner and M Wirth",
year = "2011",
language = "Deutsch",
volume = "50",
pages = "309--312",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - [Prostate-specific antigen for treatment monitoring].

AU - Graefen, Markus

AU - Fröhner, M

AU - Wirth, M

PY - 2011

Y1 - 2011

N2 - Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.

AB - Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.

KW - Humans

KW - Male

KW - Prognosis

KW - Tumor Markers, Biological/blood

KW - Prostate-Specific Antigen/blood

KW - Neoplasm Proteins/blood

KW - Prostatic Neoplasms/blood/diagnosis/therapy

KW - Humans

KW - Male

KW - Prognosis

KW - Tumor Markers, Biological/blood

KW - Prostate-Specific Antigen/blood

KW - Neoplasm Proteins/blood

KW - Prostatic Neoplasms/blood/diagnosis/therapy

M3 - SCORING: Zeitschriftenaufsatz

VL - 50

SP - 309

EP - 312

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 3

M1 - 3

ER -